Screening aims to identify prostate cancer at an early stage where curative treatment can reduce mortality. Given high false positive and false negative rates, however, the use of prostate-specific antigen (PSA) in screening has long been controversial. Recent systematic reviews comprising large randomised-controlled trials (RCTs) with long-term follow-up have demonstrated just modest benefit regarding mortality reduction compared to standard care [1,2]. Screening is also associated with overdiagnosis of clinically-insignificant tumours that never would have been diagnosed otherwise. This article is protected by copyright. All rights reserved.
BJU international. 2019 Feb 05 [Epub ahead of print]
Alexander Light, Oussama Elhage, Lorenzo Marconi, Prokar Dasgupta
GKT School of Medical Education, King's College London, Guy's Campus, St. Thomas Street, London, SE1 1UL., The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT.